Immunosuppressing medicine can be interrupted to boost COVID-19 vaccine response
Interrupting treatment of immunosuppressing medicines for two weeks can significantly improve antibody immunity provided by COVID-19 booster vaccines.
UK Government backs Fleming Centre to fight threat of drug resistant infections
The UK Government has committed £5million in seed funding to support a joint Imperial initiative to fight antimicrobial resistance.
Major study shows new insights into lasting impacts of COVID‐19 on UK population
Tens of thousands of people in England may have lasting symptoms from COVID‐19 more than a year
after infection, new analysis reveals.
New mechanism found that maintains water balance within cells
Scientists have discovered a new mechanism that allows cells to maintain their ideal water availability from second to second.
Gene-edited chickens show promise in fight against bird flu
Scientists have successfully used gene editing techniques to limit the spread of bird flu in chickens.
New multi-million research projects announced to tackle future disease threats
Imperial scientists are among those to lead ambitious new UK-based research to kickstart future vaccine development.
New spinout to develop gene therapies targeting rare lung diseases
AlveoGene will work on gene therapies for several rare lung conditions, beginning with alpha-1 antitrypsin deficiency.
Study identifies vulnerable groups least likely to have COVID-19 antibodies
Findings from the MELODY study have identified which people with compromised immune systems are less likely to have COVID-19 antibodies.
Feature
In conversation: Mental Health and Stigma with HIV, where are we 40 years on?
In this podcast series, we explore the experience of living with HIV and current research at Imperial on mental health and future treatment options.
COVID-19 spread in households linked to virus on hands and surfaces
A new study provides the first empirical evidence for transmission of SARS-CoV-2 via people’s hands and frequently touched household surfaces.
